Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.47 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192738 | 0.98 | POLB (0.67) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL29447103 | 0.98 | POLB (0.67) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL30052469 | 0.86 | POLB (0.58) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL4896660 | 0.86 | POLB (0.78) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL4465544 | 0.86 | POLB (0.78) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL23885270 | 0.86 | POLB (0.58) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL680329 | 0.84 | POLB (0.61) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL1770841 | 0.84 | POLB (0.56) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL20509438 | 0.82 | POLB (0.59) | POLBL3MBTL1MAPTNPSR1HTR2A | |
| SCHEMBL30267692 | 0.82 | POLB (0.59) | POLBL3MBTL1MAPTNPSR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001945-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1001946-B1 | QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7550597-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1687642-B1 | Screening methods for combinations of biological compounds | CENTELION (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6852712-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6846815-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-25 | — | — | US | disclosed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1001946-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000031051-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031049-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1001946-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1001945-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054158-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054157-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | HTR2A 3478/4885HTR2C 3433/4885GRIN2D 3613/4885 |
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, ABL1 | HTR2A 2780/4885HTR2C 2412/4885GRIN2D 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.